Late-Stage Development and Manufacturing of Novel Excipients for Precision Nanomedicines and Targeted Therapies

Late-Stage Development and Manufacturing of Novel Excipients for Precision Nanomedicines and Targeted Therapies

Whitepapers

Excipients are no longer passive ingredients—they’re critical to the success of precision drug delivery systems. In this whitepaper, Ardena shares insights into the development and GMP manufacturing of two novel phospholipids used in nanomedicine applications, including oncology and thermosensitive liposomes.

Gain a deeper understanding of:

– Control strategies for novel excipients

– Overcoming analytical and scalability challenges

– The regulatory implications of excipient innovation

Read the full whitepaper.

 

 

Interested in reading the full resource?

Please fill out the form to unlock the rest of the content.

Latest Resources

Our team members share deep, scientific understanding and insights into their respective fields of expertise.

Want to hear more from Ardena?

Sign up to receive drug development insights, the latest on industry trends & Ardena news.

Stay up to date with our latest news and announcements.
Get deep, scientific understanding and insights into our key fields of expertise.
See the events we're attending and register for webinars we're hosting.